leisure time -WSS

leisure time

author：focus 2025-09-14 14:45:03 - browse：9

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Protect nursing home residents from future pandemics

WSS

Vertex non

Woodcock on FDA’s accelerated approval and her next chapter

Some dementia cases could be undiagnosed liver disease

Some dementia cases could be undiagnosed liver disease

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Why we need mandatory labeling of GMO products

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

FDA drug safety: Singulair case shows systemic surveillance flaws

Virginia high school admissions case could be legal follow

Cognito secures funding to test medical device for Alzheimer's

Trump demands the U.S. pay no more for drugs than other countries … again

Vertigo drug brings hope for rare neuron disorder, Niemann

Supreme Court strikes down use of affirmative action

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Louisiana bill approved classifying abortion pills as controlled substances

leisure time

Should insurance cover cosmetic surgery?

Medical students need to learn the potent medicine of empathy

Decentralized clinical trials need collaboration to achieve wider use

Vertigo drug brings hope for rare neuron disorder, Niemann

Pharma’s losing bet in New Jersey

Woodcock on FDA’s accelerated approval and her next chapter

knowledge

Wikipedia

focus

explore